The Politics of Personalised Medicine: The personalised is political

作者:

DOI: 10.1017/CBO9780511489136.009

关键词:

摘要: Ordinary coalface knowledge This book has followed two high-profile examples of pharmacogenetics, unpacking assumptions, beliefs and contexts along the way. I have shown both how to, not get an example personalised medicine into clinical practice, explored messy intersection between industry, health service funders clinicians. chapter draws together ideas around pharmacogenetics by returning to three dichotomies introduced in 1: coalface–expectations, knowledge–resistance ordinary–revolutionary technology. Having just ordinariness Herceptin, it is this dichotomy that first turn. In case studies, pharmacogenetic tests do arise out nowhere, but rather, they are enmeshed their technical, social ethical context can only be understood those terms. Whatever claims commentators, APOE testing for Alzheimer's does raise some same issues as ‘ordinary’ susceptibility gene testing. And however revolutionary Herceptin seems when discussed on financial pages, once enters clinic becomes ordinary cancer treatment, subject institutional stresses strains, with clinicians' attitudes towards understating shaped experience other, older treatments, Tamoxifen. If, arrive, better thought ordinary, opposed revolutionary, then should alert us importance within which such used.

参考文章(296)
Allen D Roses, Pharmacogenetics and future drug development and delivery The Lancet. ,vol. 355, pp. 1358- 1361 ,(2000) , 10.1016/S0140-6736(00)02126-7
Ian O Ellis, M Dowsett, J Bartlett, R Walker, T Cooke, W Gullick, B Gusterson, E Mallon, P Barrett Lee, Recommendations for HER2 testing in the UK Journal of Clinical Pathology. ,vol. 53, pp. 890- 892 ,(2000) , 10.1136/JCP.53.12.890
Janice H. Kurth, Pharmacogenomics: Future Promise of a Tool for Identifying Patients at Risk Drug Information Journal. ,vol. 34, pp. 223- 227 ,(2000) , 10.1177/009286150003400130
Krista L. Lanctôt, Maysoon M. LouLou, Nathan Herrmann, Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. Journal of Psychiatry & Neuroscience. ,vol. 28, pp. 13- 26 ,(2003)
V. Craig Jordan, Tamoxifen: a most unlikely pioneering medicine Nature Reviews Drug Discovery. ,vol. 2, pp. 205- 213 ,(2003) , 10.1038/NRD1031
D. Slamon, G. Clark, S. Wong, W. Levin, A Ullrich, W. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. ,vol. 235, pp. 177- 182 ,(1987) , 10.1126/SCIENCE.3798106
Arthur M. Feldman, Beverly H. Lorell, Steven E. Reis, Trastuzumab in the Treatment of Metastatic Breast Cancer Anticancer Therapy Versus Cardiotoxicity Circulation. ,vol. 102, pp. 272- 274 ,(2000) , 10.1161/01.CIR.102.3.272
AM Saunders, C Hulette, KA Welsh-Bohmer, DE Schmechel, B Crain, JR Burke, MJ Alberts, WJ Strittmatter, JCS Breitner, C Rosenberg, SV Scott, PC Gaskell, MA Pericak-Vance, AD Roses, Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease The Lancet. ,vol. 348, pp. 90- 93 ,(1996) , 10.1016/S0140-6736(96)01251-2